Expert Interview
Wet AMD Treatment Landscape: In-Depth Analysis of EyePoint's EYP-1901 and 4D Molecular's 4D-150 from their recent Clinical Trials
Ticker(s): EYPT, FDMTInstitution: Wills Eye Hospital
- Assistant Professor of Ophthalmology at Thomas Jefferson University and member of the retina service at Wills Eye Hospital.
- Currently manages ~2500 patients with wet age-related macular degeneration.
- Involved as a clinical investigator in several collaborative trials and studies on various conditions including age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, inherited retinal degenerations and pediatric retinal disorders.
Considering the subgroup analyses from the Phase 2 DAVIO 2 trial, how do you assess the clinical profile and durability of EYP-1901 in treating wet AMD, especially in comparison to aflibercept?
Added By: slingshot_insightsWhat are the implications of EYP-1901 demonstrating numerical superiority in best corrected visual acuity (BCVA) and anatomic stability in patients supplement-free up to 6 months?
Added By: slingshot_insightsHow does EYP-1901 perform across different wet AMD patient types, considering variations in baseline BCVA, duration of diagnosis, and historical treatment burden?
Added By: slingshot_insightsBased on the interim data from the Phase 2 PRISM trial, how would you evaluate the safety and clinical activity of 4D-150 in patients with severe wet AMD and high treatment burden?
Added By: slingshot_insightsHow does 4D-150 compare to standard anti-VEGF therapies in terms of treatment burden reduction and maintaining visual acuity and retinal anatomy?
Added By: slingshot_insightsWith some patients being injection-free for up to 24 weeks, what are the potential long-term benefits and challenges of using 4D-150 as a one-time intravitreal injection for wet AMD?
Added By: slingshot_insightsWhat are the anticipated next steps in the clinical development of EYP-1901 and 4D-150, particularly regarding their upcoming Phase 3 trials?
Added By: slingshot_insightsGiven the results of EYP-1901 and 4D-150, how might these therapies transform the current treatment landscape and patient experience in wet AMD?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
